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To develop a peptide vaccine for cancer patients with the HLA-A26 allele, which
is a minor population worldwide, we investigated the immunological responses
of HLA-A26+ ⁄A26+ cancer patients to four different CTL epitope peptides under
personalized peptide vaccine regimens. In personalized peptide vaccine regimens,
two to four peptides showing positive peptide-specific IgG responses in pre-vac-
cination plasma were selected from the four peptide candidates applicable for
HLA-A26+ ⁄ A26+ cancer patients and administered s.c. Peptide-specific CTL and IgG
responses along with cytokine levels were measured before and after vaccina-
tion. Cell surface markers in PBMCs and plasma cytokine levels were also mea-
sured. In this study, 21 advanced cancer patients, including seven lung, three
breast, two pancreas, and two colon cancer patients, were enrolled. Their HLA-
A26 genotypes were HLA-A26:01 (n = 24), HLA-A26:03 (n = 10), and HLA-A26:02
(n = 8). One, 14, and 6 patients received two, three, and four peptides, respec-
tively. Grade 1 or 2 skin reactions at the injection sites were observed in the
majority of patients, but no severe adverse events related to the vaccination
were observed. Peptide-specific CTL responses were augmented in 39% or 22%
of patients after one or two cycles of vaccination, respectively. Notably, peptide-
specific IgG were augmented in 63% or 100% of patients after one or two cycles
of vaccination, respectively. Personalized peptide vaccines with these four CTL
epitope peptides could be feasible for HLA-A26+ advanced cancer patients
because of their safety and higher rates of immunological responses.
A s a result of recent advances in cancer immunotherapy,immune checkpoint inhibitors have achieved durable clin-
ical responses in at least one-fifth of patients with various
types of advanced cancer.(1–3) However, the clinical activity of
immune checkpoint inhibitors was dependent on the presence
of T lymphocytes at tumor sites. Therefore, clinical benefits
could not be expected in cancer patients whose tumors had no
or fewer tumor-infiltrating lymphocytes. Moreover, the clinical
efficacy of chemotherapy with cytotoxic reagents has been
well correlated with the number of tumor-infiltrating lympho-
cytes.(4) We previously reported that personalized peptide vac-
cination (PPV) rapidly induced proliferation of CD45RO+
activated lymphocytes at tumor sites in association with clini-
cal benefits in patients with advanced prostate cancer or blad-
der cancer.(5–7) These results suggest that sequential cancer
therapy consisting of PPV followed by either immune check-
point inhibitors or chemotherapy with cytotoxic reagents could
be more efficacious than monotherapy. Indeed, we recently
reported that PPV followed by chemotherapy was associated
with a favorable clinical outcome in refractory ovarian cancer
patients.(8)
Although many clinical trials of peptide-based cancer vacci-
nes for HLA-A2+ and HLA-A24+ cancer patients have been car-
ried out in the past two decades, cancer patients with the other
alleles, including HLA-A1, -A3, -A11, -A26, -A31, or -A33,
were excluded from these clinical trials because of the relatively
lower allele expression worldwide.(9,10) To develop cancer vac-
cines applicable for these minor HLA-A alleles, we previously
identified large numbers of CTL epitope peptides from alleles
other than A2 or A24, and some of them were provided for the
clinical trials of peptide vaccines for the HLA-A3 superfamily
(HLA-A11, -A31, and -A33) or HLA-A26+ cancer patients
under PPV regimens in the past 7 years.(11,12) The HLA-A26
allele is found in approximately 11% of the Japanese population,
4% of the Caucasian population in the USA, and 7.5% of the
African population of Cape Town.(10)
In this study, we retrospectively analyzed the results of PPV
for HLA-A26+ ⁄A26+ advanced cancer patients from the vari-
ous regimens of PPV carried out in the past 7 years to investi-
gate the feasibility of using PPV for HLA-A26+ ⁄A26+
advanced cancer patients from the viewpoints of safety and
immunological responses.
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Patients and Methods
Peptides. The four different CTL epitope peptides used in this
study were SART3109–118 VYDYNCHVDL, ppMAPkkk432–440
DLLSHAFFA, HNRPL501–510 NVLHFFNAPL, and WHSC2103–
111 ASLDSDPWV peptides. All were previously shown to be
capable of inducing peptide-specific and tumor-reactive CTL
activity in HLA-A26 cancer patients.(10) These peptides were
prepared under the conditions of Good Manufacturing Practice
by the PolyPeptide Laboratories (San Diego, CA, USA) and
American Peptide Company (Vista, CA, USA), as reported
previously.(7,13–18)
Patients. Patients diagnosed with cancer were eligible for
this study. They had to show positive IgG responses to at least
two of the four peptide candidates applicable for HLA-A26+
cancer patients. Other inclusion criteria were as follows: age
between 20 and 80 years; an Eastern Cooperative Oncology
Group performance status of 0 or 1 at the time of first visit;
life expectancy of at least 12 weeks; and adequate hemato-
logic, hepatic, and renal function. Exclusion criteria included:
pulmonary, cardiac, or other systemic diseases; an acute infec-
tion; a history of severe allergic reactions; pregnancy or nurs-
ing; and other inappropriate conditions for enrolment as
judged by clinicians. The protocol was approved by the Kur-
ume University (Kurume, Japan) Ethical Committee and regis-
tered with the UMIN Clinical Trials Registry (UMIN nos.
1482, 1839, 1844, 1850, 1854–1856, 1881–1883, 2908, 2984,
2987, 6493, and 10068). All patients were given a full expla-
nation of the protocol and provided their informed consent
before enrolment.
Clinical protocol. This was a phase II study to evaluate the
safety, immunological responses, and clinical benefits from the
viewpoint of overall survival in heavily treated cancer patients
under PPV. Peptides for vaccination to individual patients were
selected in consideration of the pre-existing host immunity
before vaccination, as assessed by the titers of IgG specific to
each of the four different vaccine candidates.(7,11,12,16–18) A
maximum of four peptides (3 mg ⁄ each peptide), which were
selected based on the results of HLA typing and peptide-speci-
fic IgG titers, were s.c. administered with incomplete Freund’s
adjuvant (Montanide ISA51; Seppic, Paris, France) once a
week for 6 consecutive weeks (UMIN nos. 1482, 1839, 1844,
1850, 1854–1856, 1881–1883, 6493, and 10068), or once a
week for 4 consecutive weeks followed by four biweekly treat-
ments (UMIN nos. 2908, 2984, and 2987) as the first cycle.
After the first cycle of vaccinations, up to four antigen pep-
tides that were reselected according to the titers of peptide-
specific IgG were given six or eight times on a biweekly basis.
After the first cycle of vaccinations, up to four antigen pep-
tides that were reselected again were given every 4 weeks
until the 24th vaccination. During the PPV, patients were



















1 26:01 26:03 Lung Small cell
carcinoma
70 M IV 2035 1 1  +
2 26:01 26:03 Lung Squamous cell
carcinoma
65 M IV 1180 0 1  +
3 26:01 26:03 Lung Adenocarcinoma 72 M Rec. 1034 0 0  
4 26:01 26:03 Lung Adenocarcinoma 56 F Rec. 1134 0 3 + 
5 26:01 26:03 Lung Adenocarcinoma 70 M III 1007 0 1 + 
6 26:01 Lung Adenocarcinoma 75 M Rec. 1189 0 3 + 
7 26:01 26:02 Lung Adenocarcinoma 69 M IV 1005 0 3 + +
8 26:01 Breast Invasive ductal
carcinoma
55 F Rec. 1004 0 2 + 
9 26:01 Breast Invasive ductal
carcinoma
68 F IV 1550 1 6 + 
10 26:03 Breast Mucinous
carcinoma
55 F Rec. 1390 0 3 + +
11 26:01 26:03 Pancreas Adenocarcinoma 74 M I 2011 0 0  
12 26:02 Pancreas Adenocarcinoma 64 M IV 1803 0 1 + 
13 26:01 26:02 Colon Adenocarcinoma 60 M IV 1365 0 4 + +
14 26:01 Colon Adenocarcinoma 51 F Rec. 1282 0 5 + +
15 26:01 26:03 Prostate Adenocarcinoma 62 M IV 1492 0 1  +
16 26:01 Stomach Adenocarcinoma 70 M IV 1200 0 0  
17 26:01 26:03 Liver Hepatocellualar
carcinoma
46 M IV 1050 0 4 + +
18 26:01 Kidney Clear cell type 53 M Rec. 1673 0 1  +
19 26:02 Bladder Transitional cell
carcinoma
66 M Rec. 1612 0 1 + 
20 26:01 26:02 Uterus Leiomyosarcoma 52 F Rec. 1430 0 1 + 
21 26:01 26:02 Oval Adenocarcinoma 65 F Rec. 1300 1 2 + +
†Other therapy included radiation therapy, hormone therapy and intra-arterial injection therapy. ‡Patients are alive. +, Used; , not used;
F, female; M, male; NA, not assessed; OS, overall survival; PD, progression desease; PS, performance status; Rec., Recurrence; SD, stable disease.
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allowed to receive combination therapies, such as chemothera-
pies or radiotherapies. Adverse events were monitored accord-
ing to the National Cancer Institute Common Terminology
Criteria for Adverse Events version 3.0. Complete blood
counts and serum biochemistry tests were carried out before
and after each cycle of vaccinations. Tumor assessments by
computed tomography or MRI scans were carried out before
and after PPV, and evaluated according to Response Evalua-
tion Criteria in Solid Tumors version 1.1.
Laboratory markers. Humoral immune responses specific to
each of the four peptide candidates were determined by pep-
tide-specific IgG levels using the Luminex system (Luminex,
Austin, TX, USA), as previously reported.(19–22) If the titers of
peptide-specific IgG to at least one of the vaccinated peptides
at the end of the first cycle were more than twofold higher
than those in the prevaccination plasma, the changes were con-
sidered to be significant, as previously reported. The CTL
responses specific to the vaccinated peptides were evaluated
by c-interferon ELISPOT assays using PBMCs before and at
the end of the first cycle, as previously reported.(19–22)
Cell surface markers and cytokines. As cell surface markers,
myeloid-derived suppressor cells (CD33, CD11b, CD14, CD15,
CD3, CD16, CD19, CD56, and HLA-DR), regulatory T cells
(CD4, CD25, and FoxP3), BTLA, PD-1, CTLA-4, and LAG-3
were measured by a BD FACSCanto II System with FACS
Diva software (BD Biosciences, San Diego, CA, USA). In
addition, the levels of interleukin (IL)6, IL8, and c-interferon-
induced protein 10 (IP-10) in plasma before and after one cycle
of vaccination were examined by ELISA using kits from
eBioscience (San Diego, CA, USA), as reported previously.(23)
Statistical analyses. All data were analyzed retrospectively.
Comparison of each group was carried out using ANOVA. Over-
all survival was calculated from the first day of peptide vacci-
nation until the date of death or the last date when the patient
was known to be alive. Values of P < 0.05 were considered to
indicate statistical significance. All statistical analyses were
carried out using JMP software, version 12 (SAS Institute,
Cary, NC, USA).
Results
Patients’ characteristics. Between December 2008 and August
2014, 21 A26+ ⁄A26+ advanced cancer patients were enrolled
to this study. Their genotypes were A26:01 (n = 24), HLA-
A26:03 (n = 10), and HLA-A26:02 (n = 8). Their diagnosis
was lung cancer (n = 7), breast cancer (n = 3), pancreatic can-
cer (n = 2), colon cancer (n = 2), and one case each of pros-
tate cancer, stomach cancer, liver cancer, kidney cancer,
bladder cancer, uterine cancer, and ovarian cancer. The
patients’ characteristics are shown in Table 1. The median age
was 65 years (range, 46–75 years). The median lymphocyte




















 1 +   4 70 Death
+ 1 +   4 80 Death
+ 0    17 435‡ SD
 2 +   24 692 SD
+ 0    13 312‡ SD
 3 + +  17 367 SD
 2 + +  3 47‡ Unknown
 2 +   9 381 PD
 0    1 20 Death
+ 0   + 18 703‡ SD
 0    32 1058‡ SD
 1 +   6 74 Death
+ 0    4 54 Death
- 2 + +  9 202 SD
+ 2 +  + 30 949 SD
 1 +   12 701‡ SD
+ 1  +  6 209 SD
 1  +  9 1820 SD
 1 +   12 346‡ PD
 1 +   12 489 SD
 0    18 642‡ SD
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2035 ⁄mm3). Performance status at the time of enrolment was
grade 0 (n = 18) or grade 1 (n = 3). The numbers of previous
chemotherapy regimens were one (n = 8), two (n = 2), three
(n = 4), and more than three (n = 4). Fifteen patients received
combined chemotherapy or other therapy such as hormone
therapy along with PPV. Sixteen patients completed the first
cycle of vaccinations, whereas the remaining five patients did
not due to rapid disease progression. The median number of
vaccinations was 12 (range, 1–32).
Adverse events. Table 2 shows the adverse events during the
PPV. Grade 1 or 2 injection site reactions were observed in 15
of 21 (71.4%) patients. Severe adverse events were seen in
four patients (grade 3, two neutropenia and one hypertension;
grade 4, one neutropenia). All of them were concluded to be
not directly associated with the PPV, but with disease progres-
sion or combined therapy according to evaluation by the inde-
pendent safety evaluation committee.
Immune responses. Both peptide-specific CTL and IgG
responses were analyzed in blood samples from 21, 16, and 11
patients before vaccinations, after the first cycle of vaccina-
tions, and after the second cycle of vaccinations, respectively.
Peptide-specific IgG reactive to each of the 31 different pep-
tides, including both the vaccinated and non-vaccinated pep-
tides, were measured by the Luminex system. The numbers of
peptides used for the first cycle of vaccinations were two,
three, and four in 1, 14, and 6 patients, respectively. The IgG
responses before vaccination were observed in all the patients.
The IgG responses specific to at least one of the vaccinated
peptides were increased after the first cycle of vaccination in
11 of 16 (69%) patients tested, and after the second cycle of
vaccination in all 11 patients tested (Table 3).
The CTL responses to the vaccinated peptides before vacci-
nation were detectable in 3 of 13 (23%) patients (Table 3).
They became detectable after the first cycle of vaccination in 5
of 13 (38%) patients and after the second cycle of vaccination
in 2 of 9 (22%) patients.
Collectively, after the first cycle of vaccination, 3 patients
showed both increased CTL and IgG responses to the vacci-
nated peptides, 11 of 16 patients showed either increased CTL
or IgG responses, and the remaining 5 patients showed neither
CTL nor IgG boosting. All 11 patients showed either increased
CTL or IgG responses to the vaccinated peptides after the sec-
ond cycle of vaccination.
Cell surface marker and inflammatory cytokines. We also mea-
sured immune cell subsets in pre- and post-vaccination (after
the first cycle) of PBMCs, including myeloid-derived suppres-
sor cells, regulatory T cells, or BTLA-, PD-1-, CTLA-4-, and
LAG-3-postive cells, by flow cytometry. In addition, we mea-
sured pre- and post-vaccination (after the first cycle) of plasma
levels of cytokines, including IL6, IL8, and IP-10. Neither the
immune cell subsets nor the cytokine levels in prevaccination
samples were significantly different from those of the post-vac-
cination samples (Table 4).
Clinical response. Best clinical responses were evaluated by
radiological findings. There were no cases of complete
response, no cases of partial response, 13 cases of stable dis-
ease (SD), and 7 cases of progressive disease (PD) (Table 1).
Computed tomography findings of 1 patient of SD case before
vaccination and after 2 cycles of vaccination are shown in Fig-
ure 1. This case (case #3 in Table 1) was a 72-year-old man
with recurrent lung cancer after radiation therapy treated with
PPV alone. At 1 year after the 1st vaccination, the tumor had
grown slightly, but showed stable disease (SD). Both the cellu-
lar immune responses and IgG responses to vaccinated pep-
tides were well boosted in this case (case #3 in Table 3).
Discussion
To the best of our knowledge, this is the first clinical trial of
peptide-based cancer vaccines for HLA-A26+ cancer patients.
The HLA-A26 allele is found in approximately 11% of the
Japanese population and includes various genotypes.(10) The
frequencies of the different HLA-A26 genotypes in the Japa-
nese population have been reported as follows: HLA-A2601:
7.35%; HLA-A2603: 2.23%; HLA-A2603: 1.81%; HLA-
A2605: 0.07%; and HLA-A2606: 0.01%.(24) Their HLA-A26
genotypes of the 21 patients in this study were HLA-A26:01
(n = 24), HLA-A26:03 (n = 10), and HLA-A26:02 (n = 8).
Thus the trend among the present patient population was simi-
lar to that for Japan as a whole, although it is difficult to com-
pare the two sets of results because of the extremely small
size of our subject group (21 patients).
From the viewpoint of adverse events, a grade 1 or 2 injec-
tion site reaction was observed in 70% of the patients. Severe
adverse events were seen in 4 patients, and all of them were
concluded to be not directly associated with the PPV, but with
the disease progression or combined therapy. These results
were consistent with the previous results on PPV for the HLA-
A24+ or -A2+ cancer patients reported previously.(11,12)
This study showed the successful boosting of HLA-A26
restricted peptide-specific immune responses in blood samples
after the 6th vaccination of PPV. Boosting for peptide-specific
IgG responses, which were clearly detectable in all 21 patients,
Table 2. Adverse events in HLA-A26+ ⁄ A26+ cancer patients (n = 21)
treated with personalized peptide vaccine regimens
Grade 1 Grade 2 Grade 3 Grade 4
No. % No. % No. % No. %
Injected site reaction 8 38.1 7 33.3 0 0.0 0 0.0
General disorder
Fever 0 0.0 1 4.8 0 0.0 0 0.0
Blood ⁄ bone marrow
Anemia 0 0.0 3 14.3 0 0.0 0 0.0
Leukopenia 0 0.0 0 0.0 0 0.0 0 0.0
Neutropenia 0 0.0 1 4.8 2 9.5 1 4.8
Lympocytopenia 1 4.8 3 14.3 0 0.0 0 0.0
Thrombocytopenia 1 4.8 0 0.0 0 0.0 0 0.0
Metabolic and laboratory
AST increased 3 14.3 0 0.0 0 0.0 0 0.0
ALT increased 1 4.8 2 9.5 0 0.0 0 0.0
c-GTP increased 4 19 0 0.0 0 0.0 0 0.0
ALP increased 0 0.0 0 0.0 0 0.0 0 0.0
Hypoalbuminemia 7 33.3 2 9.5 0 0.0 0 0.0
Creatinine increased 1 4.8 0 0.0 0 0.0 0 0.0
Electrolyte imbalance 0 0.0 1 4.8 0 0.0 0 0.0
Neurological
Tumor pain 2 9.5 1 4.8 0 0.0 0 0.0
Vascular disorder 0 0.0 0 0.0 0 0.0 0 0.0
Hypertension 0 0.0 0 0.0 1 4.8 0 0.0
Gastrointestinal disorder
Diarrhea 0 0.0 1 4.8 0 0.0 0 0.0
Skin and subcutaneous tissue disorder
Alopecia 0 0.0 1 4.8 0 0.0 0 0.0
Rash acneiform 1 4.8 0 0.0 0 0.0 0 0.0
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspar-
tate aminotransferase; c-GTP, c-glutamyl transpeptidase.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
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Table 3. Immune responses after first and second cycles of personalized peptide vaccination
Patient no. Peptide
IgG responses to vaccinated peptide† CTL response‡
Pre Post 1 cycle Post 2 cycles Pre Post 1 cycle Post 2 cycles
3 SART3-109 60 43 4625 0 0 0
ppMAPkkk-432 103 96 868 0 554 0
WHSC2-103 19 16 31 238 0 0
4 SART3-109 ND ND 746 NA NA NA
ppMAPkkk-432 353 319 281 NA NA NA
HNRPL-501 122 124 30 500 NA NA NA
WHSC2-103 229 217 729 NA NA NA
5 ppMAPkkk-432 ND 25 16 0 0 0
HNRPL-501 172 197 1530 0 0 0
WHSC2-103 4115 2460 1869 0 0 0
6 SART3-109 21 55 21 478 NA NA NA
HNRPL-501 13 23 7715 NA NA NA
WHSC2-103 ND ND 12 NA NA NA
8 SART3-109 109 110 NA 200 0 NA
HNRPL-501 62 51 NA 149 0 NA
WHSC2-103 24 22 NA 0 0 NA
10 SART3-109 ND ND 388 NA NA 0
ppMAPkkk-432 ND ND 55 NA NA 0
HNRPL-501 17 185 27 281 0 722 0
WHSC2-103 34 42 119 0 0 0
11 SART3-109 23 20 9540 0 0 0
ppMAPkkk-432 ND 11 11 0 0 0
HNRPL-501 ND ND 10 0 0 0
WHSC2-103 22 14405 5951 0 0 0
12 SART3-109 76 76 NA 0 0 NA
ppMAPkkk-432 86 94 NA 0 0 NA
HNRPL-501 43 39 NA 0 0 NA
WHSC2-103 642 654 NA 0 0 NA
14 SART3-109 18 8432 NA 0 0 NA
HNRPL-501 253 21 599 NA 0 0 NA
WHSC2-103 14 43 NA 0 0 NA
15 SART3-109 69 210 8276 0 0 0
ppMAPkkk-432 141 144 18 124 0 223 816
WHSC2-103 82 ND 10 876 0 0 0
16 SART3-109 23 ND 20 743 0 0 0
WHSC2-103 42 112 7474 0 0 0
17 SART3-109 132 ND NA NA NA NA
ppMAPkkk-432 200 ND NA NA NA NA
HNRPL-501 146 ND NA NA NA NA
18 SART3-109 2930 12 149 NA 359 132 NA
ppMAPkkk-432 15 16 NA 0 0 NA
HNRPL-501 454 473 NA 0 0 NA
19 SART3-109 29 280 25 446 0 0 0
ppMAPkkk-432 248 290 36 864 0 0 486
HNRPL-501 ND 11 7523 0 0 0
WHSC2-103 3086 2906 2847 0 0 0
20 SART3-109 11 16 23 089 0 0 0
ppMAPkkk-432 15 21 41 0 0 0
HNRPL-501 ND ND 24 0 0 0
21 ppMAPkkk-432 62 87 134 0 0 0
HNRPL-501 18 38 589 36 619 0 0 0
WHSC2-103 23 66 1877 0 342 0
†If the titers of peptide-specific IgG at the end of the first or second cycles were more than twofold higher than those in the prevaccination
plasma, or were newly appeared, these changes were considered to be enhanced. The augmented IgG responses are underlined. ‡CTL responses
were determined by the number of spots per 105 PBMCs reactive with the vaccinated peptides in c-interferon ELISPOT assay before and after the
first or second cycles of vaccination. The augmented T cell responses are underlined. NA, not assessed; ND, not detected.
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was especially apparent in 63% or 100% of patients after the
1st cycle or 2nd cycle of vaccination, respectively. We have
reported that boosting of IgG responses is well correlated with
overall survival.(21,25)
In contrast to IgG responses, peptide-specific CTL responses
of each of the vaccine candidates were rarely detectable. There
were several possible explanation for this discrepancy between
IgG and CTL boosting. One of them could be deletion or
depression of the expression of HLA-A26 molecules on the
surface of cancer cells from these HLA-A26 homogenous
advanced cancer patients. PBMCs from HLA-A26 heteroge-
neous advanced cancer patients were provided for in vitro
determination of these 4 peptides that could induce peptide-
specific CTL activity for HLA-A26+ cancer patients as
reported previously.(10) Their clinical stages were not as
advanced as to those of the 21 patients who received PPV in
this study. The other explanation could be that the numbers of
pooled peptides were too small to correspond to antigenic
heterogeneity of tumor cells and also diverse immune
responses among cancer patients. Indeed, 9 of 30 (30%) HLA-
A26+ ⁄A26+ cancer patients could not be enrolled in this study
because they did not have more than 2 positive IgG responses
among the 4 pooled peptides. Therefore, the development of
additional HLA-A26 restricted peptides is needed. In addition,
if patients have both the HLA-A2, -A24, or A3 superfamily
and HLA-A26, it might be appropriate to use both the peptides
matched with the HLA-A2, -A24, or A3 superfamily and those
matched with the HLA-A26 allele, as we have been conduct-
ing the vaccination using both the peptides with the successful
boosting of peptide-specific CTL responses as reported previ-
ously.(11,12,21,23)
This was a small study with a limited number of patients for
investigation of the PPV-induced immunological responses in
HLA-A26+ ⁄A26+ cancer patients. Therefore, clinical benefits
were not set as the secondary objective. However, it could be
important to provide available information on the clinical out-
come of these patients under PPV. We have previously
reported the possibility of extending the overall survival in
clinical trials of PPV in each organ cancer patients, and espe-
cially for patients who exhibit humoral responses and T cell
responses. As a result, there were no complete response, no
partial response, 13 stable disease (SD), 7 progressive disease,
and 1 unknown. Five patients (one each with stage IV small-
cell lung cancer, adenocarcinoma lung cancer, invasive ductal
breast cancer, pancreatic cancer, and colon cancer patients)
could not receive the first cycle of vaccination because of
Table 4. Cell surface markers and cytokines before and after one
cycle of personal peptide vaccine†
Before After 1 cycle
P-
value‡
MDSCs, %lymphocytes 0.84 (0.25–1.70) 0.96 (0.67–2.13) 0.48
Regulatory T cells, %
lymphocytes
1.33 (0.55–2.97) 1.54 (0.90–3.17) 0.23
BTLA+CD4+ T cells, %
lymphocytes
29.9 (15.8–54.8) 31.4 (20.1–44.8) 0.51
BTLA+CD8+ T cells, %
lymphocytes
13.6 (7.9–21.2) 14.2 (8.0–24.5) 0.56
PD-1+CD4+ T cells, %
lymphocytes
1.37 (0.45–2.54) 1.63 (0.40–3.38) 0.13
PD-1+CD8+ T cells, %
lymphocytes
0.56 (0.25–1.01) 0.47 (0.17–0.93) 0.06
CTLA-4+CD4+ T cells, %
lymphocytes
0.05 (0.02–0.16) 0.06 (0.02–0.13) 0.65
CTLA-4+CD8+ T cells, %
lymphocytes
15.1 (7.4–27.3) 16.0 (11.6–25.9) 0.57
LAG-3+CD4+ T cells, %
lymphocytes
0.18 (0.03–0.53) 0.23 (0.06–0.47) 0.28
LAG-3+CD8+ T cells, %
lymphocytes
0.43 (0.06–1.58) 0.45 (0.10–1.33) 0.58
IL6, pg ⁄ mL 9.88 (5.30–37.67) 7.76 (5.15–17.71) 0.24
IL8, pg ⁄ mL 22.2 (1.8–86.6) 26.1 (2.2–149.8) 0.79
IP–10, pg ⁄ mL 150 (63–354) 172 (110–412) 0.45
†Eleven of 16 patients who ended one cycle of treatment with per-
sonal peptide vaccine were measured. Five patients could not be mea-
sured because their samples were insufficient. ‡Paired t-test was used
to examine P-values. IL, interleukin; IP-10, c-interferon-induced pro-
tein 10; MDSCs, myeloid-derived suppressor cells.
(a) (b) (c)
Fig. 1. Clinical responses to personalized peptide vaccination (PPV). Computed tomography findings of a patient with stable disease. (a) At
diagnosis of lung cancer, 1 year before first vaccination. (b) At recurrence of lung cancer, 3 months before first vaccination. Before this time, the
patient had undergone radiation therapy and achieved complete response. (c) One year after first vaccination, the tumor had increased slightly,
but stable disease was maintained. Arrows indicate tumur site.
© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd
on behalf of Japanese Cancer Association.
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rapid disease progression and died within 80 days of the first
vaccination. The other 16 patients received at least six vacci-
nations (median, 15 vaccinations; range, 3–32 vaccinations),
and their median survival time was 949 days (range, 47–
1820 days). Best clinical responses were SD (n = 12), progres-
sive disease (n = 2), and unknown (n = 1).
In this study, there was no significant difference in either
cell surface markers or inflammatory cytokines between before
and after PPV. This could be mainly due to small numbers of
patients with various types of cancers. These results, however,
were partly similar to the previous cell surface marker study in
which PPV induced increases and decreased the frequency of
PD1+CD4+ T cells and that of PD1+CD8+ T cells in associa-
tion with favorable overall survival.(25)
In summary, this study showed that PPV with these four dif-
ferent CTL epitope peptides could be feasible for HLA-A26+
advanced cancer patients because of the safety of the regimens
and high rates of immunological responses.
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